Background for Rosetta Genomics (ROSG)

Basic Info
Stock symbol:ROSG
Website:http://www.rosettagenomics.com/
IPO date: 2/27/07
Total shares outstanding: 11.8 million
Market Cap: $77.5 million as of 4/4/07
Other reviews: History of attempts at Rosetta Genomics’ IPO and some background info
If you know of others please add them in the comments.
Drugs/Platforms
Diagnostics:
Cancer of Unknown Primary (CUP) diagnostic test using miRNAs
Prostate cancer diagnostic test using miRNAs (with Asuragen)
Drugs in development: […]

How Rosetta Genomics Finds Micro RNAs

This is the second in a series of posts analyzing Rosetta Genomics stock. If you haven’t already, you may want to read my primer on what a micro RNA is and how companies can capitalize on them.
There’s really two ways to find a miRNA. The first is to isolate RNA from the […]

What’s yours is mine: Rosetta Genomics partners

This is the third in a series of posts analyzing Rosetta Genomics stock.
When analyzing Synta, I decided to take a pass on buying their stock right now because I was worried that there wouldn’t be anyone to partner with them; Rosetta seems to have the opposite problem. Almost every product they’re developing has a […]

Good use of IPO funds?

Does anyone have any idea why a company without any products to sell might be using Google adwords to advertise? I saw the image to the right on my blog the other day.
Here’s some potential ideas I came up with:

They’re trying to get even more research collaborations (but I would think anyone in the […]

Designing Better Diagnostic Tests for Diseases

This is the fifth in a series of posts analyzing Rosetta Genomics stock.
Currently most tests for diseases look at protein (or sometimes mRNA) levels in the cells to determine if the cells are diseased. A good example of this is the prostrate specific antigen (PSA) test for prostrate cancer. The test looks at […]

Rosetta Genomics: Final decision, buy or hold off?

This is the sixth in a series of posts analyzing Rosetta Genomics stock.
The best thing that Rosetta Genomics has going for it is that it has a huge amount of intellectual property. They have patents on (or have licensed rights to) hundreds of miRNAs. Essentially, at this point, an investment in Rosetta Genomics […]